Author

R. Chiari

Observed institution: Ospedali Riuniti Marche Nord

OpenAlex ID: A5082214166

EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

2022 · F. Cappuzzo, R. Chiari, et al. · Journal of Thoracic Oncology · 3

91P Observational retro-prospective study on immune checkpoint inhibitors (ICIs) treatment duration in patients with advanced non-small cell lung cancer (aNSCLC) (I-STOP study)

2024 · M. Gemelli, E. Sala, et al. · ESMO Open · 1

904MO Anthracycline-related cardiotoxicity in breast cancer patients carrying mutational signature of homologous recombination deficiency (HRD)

2022 · L. Incorvaia, A. Fiorino, et al. · Annals of Oncology · 1

P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

2022 · L. Landi, M. Tiseo, et al. · Journal of Thoracic Oncology · 1

236P Adjuvant osimertinib in resected EGFR-mutated NSCLC: A real-world analysis from the Italian ATLAS registry

2026 · M.L. Reale, F. Passiglia, et al. · ESMO Open

P3.12.15 Activity and Tolerability of MET Tkis in METex14 NSCLC: Updated Real-World Data From the Italian Biomarker Atlas Database

2025 · M.L. Reale, A. Mogavero, et al. · Journal of Thoracic Oncology

Works count: 6

Citation count: 6

H-index: 1

I10-index: